Time to Transform the Glaucoma Treatment Paradigm
SLT is an effective intervention for newly-diagnosed patients – and now we can prove it
Gus Gazzard | | Opinion
In April this year, we published the results of our six-year NIHR-funded trial assessing primary treatment for newly-diagnosed glaucoma (1). We compared two interventions; selective laser trabeculoplasty – a well-known, but less widely adopted first-line treatment – and the current standard of care, eye drops. Seven hundred and eighteen patients were randomly allocated to a group and monitored to establish which intervention was more effective in lowering intraocular pressure (IOP). We managed to retain over 90 percent of those patients, which is not only a feat in itself, but a major metric of a successful study. The results were surprising – even to us.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.